Clareo Health | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
25–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Manifest HD diagnosis, defined as a DCL score of 4
Independence Scale (IS) score \>= 70
Genetically confirmed disease by direct DNA testing with a CAP score \>400
Clinical assessment to ensure individual has intact functional independence at baseline to maintain self-care and core activities of daily living (ADLs).
You may not be if
Any serious medical condition or clinically significant laboratory, or vital sign abnormality or claustrophobia at screening that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study drug
